<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582332</url>
  </required_header>
  <id_info>
    <org_study_id>2015/5965</org_study_id>
    <nct_id>NCT03582332</nct_id>
  </id_info>
  <brief_title>Serum Creatinine Change / Renal Adverse Effect With Use of Non-steroidal Painkillers in Axial Spondyloarthritis Patients</brief_title>
  <official_title>Effect of Continuous Administration of Different Therapeutic Dosages of Indomethacin and Etoricoxib in the Management of Axial Spondyloarthritis: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      2 Non-steroidal anti-inflammatory drugs (NSAIDs), indomethacin and etoricoxib were prescribed
      sequentially in Axial Spondyloarthritis patients according to the internationally accepted
      guidelines to determine serum creatinine change with NSAIDs use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study had 2 phases. In phase 1, Patients of axial Spondyloarthritis were randomized into
      2 groups; group A and group B. they were put on indomethacin 150 mg/day and indomethacin 100
      mg/day respectively and were followed up at 3rd week. Those who had normal serum creatinine
      and responded with the drug were followed up to 24th week. Those who did not respond were
      excluded from phase 1 and were enrolled in phase 2. Non-responders of indomethacin 150mg and
      indomethacin 100 mg were put on etoricoxib 90 mg and etoricoxib 60 mg respectively. Again
      followed up to 24th week.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2, 2016</start_date>
  <completion_date type="Actual">June 23, 2016</completion_date>
  <primary_completion_date type="Actual">June 23, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum creatinine change</measure>
    <time_frame>3rd week and 24th week</time_frame>
    <description>change in serum creatinine &gt;25% from baseline with use of indomethacin and etoricoxib in Axial Spondyloarthritis patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bath Ankyiosing Spodylitis Disease Activity Index (BASDAI)</measure>
    <time_frame>3rd week and 24th week</time_frame>
    <description>&lt;4 responded to treatment, 4 or more means not responded to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankylosing Spondylitis Disease Activity Score (ASDAS)</measure>
    <time_frame>3rd week and 24th week</time_frame>
    <description>ASDAS: &lt;1.3 between &quot;inactive disease&quot; and &quot;moderate disease activity&quot;, &lt;2.1 between &quot;moderate disease activity&quot; and &quot;high disease activity&quot;, and &gt;3.5 between &quot;high disease activity&quot; and &quot;very high disease activity&quot;</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Group A in phase 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Indomethacin 75 mg, extended release capsule twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B in phase 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Indomethacin 25 mg capsule, 2 capsule twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A in phase 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etoricoxib 90 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B in phase 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etoricoxib 60 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin SR, 75 Mg Oral Capsule, Extended Release</intervention_name>
    <description>Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily</description>
    <arm_group_label>Group A in phase 1</arm_group_label>
    <other_name>indomethacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin 25 Mg Oral Capsule</intervention_name>
    <description>Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily</description>
    <arm_group_label>Group B in phase 1</arm_group_label>
    <other_name>indomethacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib 90 mg</intervention_name>
    <description>Etoricoxib 90 mg once daily orally</description>
    <arm_group_label>Group A in phase 2</arm_group_label>
    <other_name>Etoricoxib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib 60 mg</intervention_name>
    <description>Etoricoxib 60 mg once daily orally</description>
    <arm_group_label>Group B in phase 2</arm_group_label>
    <other_name>Etoricoxib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SpA (axial) patients according to Assessment of Spondyloarthritis International
             Society (ASAS) criteria with BASDAI &gt; 4

        Exclusion Criteria:

          -  Inadequate response to therapeutic dose of indomethacin or etoricoxib, taken for at
             least 2 weeks continuously

          -  Abnormal serum creatinine : serum creatinine &gt;1.3 mg/dl

          -  Abnormal SGPT: SGPT &gt; 40 U/L

          -  Hypertension: Systolic blood pressure &gt; 140 mm Hg and/ or diastolic blood pressure &gt;90
             mm Hg or on anti-hypertensive drug

          -  Dyspepsia or active peptic ulcer disease : upper abdominal discomfort or upper
             abdominal pain related with food or peptic ulcer disease diagnosed by upper
             gastrointestinal endoscopy

          -  Diabetes mellitus: abnormal random plasma glucose or diagnosed case of diabetes
             mellitus

          -  Ischemic heart disease: history of angina or ECG changes suggestive of ischemic heart
             disease

          -  Active congestive heart failure: pedal edema with tender hepatomegaly with raised JVP
             or diastolic dysfunction on echocardiography

          -  Asthma: diagnosed case of asthma or rhonchi on chest auscultation

          -  Bleeding problems: having a history of prolonged bleeding

          -  Pregnancy: missed period followed by positive pregnancy test

          -  Simultaneous use with certain medications such as warfarin, phenytoin, cyclosporine,
             probenecid, lithium, digoxin, ACE inhibitor, thiazide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khandker Mahbub-Uz-Zaman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resident</affiliation>
  </overall_official>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Khandker Mahbub-Uz-Zaman</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

